CN110769854B - 组合使用的抗真菌剂 - Google Patents

组合使用的抗真菌剂 Download PDF

Info

Publication number
CN110769854B
CN110769854B CN201880033777.4A CN201880033777A CN110769854B CN 110769854 B CN110769854 B CN 110769854B CN 201880033777 A CN201880033777 A CN 201880033777A CN 110769854 B CN110769854 B CN 110769854B
Authority
CN
China
Prior art keywords
therapeutic agent
combination
antifungal
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880033777.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110769854A (zh
Inventor
D·A·安古洛·冈萨雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scynexis Inc
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of CN110769854A publication Critical patent/CN110769854A/zh
Application granted granted Critical
Publication of CN110769854B publication Critical patent/CN110769854B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN201880033777.4A 2017-04-10 2018-04-04 组合使用的抗真菌剂 Active CN110769854B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483647P 2017-04-10 2017-04-10
US62/483,647 2017-04-10
PCT/US2018/026088 WO2018191077A1 (en) 2017-04-10 2018-04-04 Antifungal agents used in combination

Publications (2)

Publication Number Publication Date
CN110769854A CN110769854A (zh) 2020-02-07
CN110769854B true CN110769854B (zh) 2023-01-13

Family

ID=62063223

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880033777.4A Active CN110769854B (zh) 2017-04-10 2018-04-04 组合使用的抗真菌剂

Country Status (13)

Country Link
US (2) US11110102B2 (enExample)
EP (1) EP3609539A1 (enExample)
JP (2) JP7263313B2 (enExample)
KR (2) KR102683355B1 (enExample)
CN (1) CN110769854B (enExample)
AR (1) AR113221A1 (enExample)
AU (1) AU2018253031B2 (enExample)
CA (1) CA3059225A1 (enExample)
EA (1) EA201992413A1 (enExample)
MA (1) MA49889A (enExample)
MX (1) MX2019012116A (enExample)
TW (1) TWI806861B (enExample)
WO (1) WO2018191077A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661503B1 (en) * 2017-08-04 2022-09-07 Scynexis, Inc. Antifungal agents with enhanced activity in acidic ph
CN113631165A (zh) * 2019-02-27 2021-11-09 西尼克斯公司 用于治疗或预防肺囊虫属肺炎的三萜类抗真菌剂
CA3140637A1 (en) * 2019-05-16 2020-11-19 Scynexis, Inc. Antifungal agents, like ibrexafungerp for candida auris decolonization

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
AU2007245024B2 (en) 2006-04-03 2012-09-06 Scynexis, Inc. Antifungal agents
CN104877001B (zh) * 2008-08-12 2020-07-03 西尼克斯公司 抗真菌制剂
EA018337B1 (ru) * 2008-08-12 2013-07-30 Мерк Шарп Энд Дом Корп. Противогрибковые средства
AU2015348043B2 (en) * 2014-11-21 2019-08-22 F2G Limited Antifungal agents
US10174074B2 (en) 2015-01-19 2019-01-08 Scynexis, Inc. Salts and polymorphs of SCY-078

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Amphotericin B- and Voriconazole-Echinocandin Combinations against Aspergillus spp.: Effect of Serum on Inhibitory and Fungicidal Interactions;Antigoni Elefanti等;《Antimicrobial Agents and Chemotherapy》;20130715;第57卷(第10期);第4656–4663页 *

Also Published As

Publication number Publication date
TW201842915A (zh) 2018-12-16
EP3609539A1 (en) 2020-02-19
JP7574268B2 (ja) 2024-10-28
WO2018191077A1 (en) 2018-10-18
JP2023030113A (ja) 2023-03-07
AR113221A1 (es) 2020-02-19
MX2019012116A (es) 2019-11-21
TWI806861B (zh) 2023-07-01
CA3059225A1 (en) 2018-10-18
AU2018253031B2 (en) 2024-04-11
BR112019021138A2 (pt) 2020-05-12
US20220202833A1 (en) 2022-06-30
JP7263313B2 (ja) 2023-04-24
KR20240110109A (ko) 2024-07-12
US11110102B2 (en) 2021-09-07
EA201992413A1 (ru) 2020-03-16
MA49889A (fr) 2020-06-24
KR102683355B1 (ko) 2024-07-10
CN110769854A (zh) 2020-02-07
JP2020513037A (ja) 2020-04-30
US20180325919A1 (en) 2018-11-15
KR20190133251A (ko) 2019-12-02
AU2018253031A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
JP7574268B2 (ja) 併用される抗真菌剤
US20230364067A1 (en) Antifungal agents with enhanced activity in acidic ph
EP3917534B1 (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40022879B (en) Antifungal agents used in combination
BR112019021138B1 (pt) Combinação farmacêutica, e, uso de uma combinação farmacêutica
HK40022879A (en) Antifungal agents used in combination
US20260000656A1 (en) Antifungal agents with enhanced activity in acidic ph
HK40091926A (en) Antifungal agents with enhanced activity in acidic ph
EA047299B1 (ru) Фармацевтическая комбинация тритерпеноидного производного энфумафунгина с изавуконазолом и ее применение для лечения инвазивного аспергиллеза легких
HK40030410A (en) Antifungal agents with enhanced activity in acidic ph
HK40030410B (en) Antifungal agents with enhanced activity in acidic ph
EA047126B1 (ru) Противогрибковое средство для лечения или профилактики инфекции вульвовагинального кандидоза
HK40062374B (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40062374A (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40022879

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant